

ASX Announcement ([ASX: AXE](#))

4 March 2026

## 1H FY26 Update - Presentation

Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”) is pleased to enclose a copy of the presentation to be delivered by Chief Executive Officer, Simon Ruffell, for the Company’s 1H FY26 update.

The webinar will commence at 11:00am AEDT today and will be followed by a Q&A session.

To attend, please register at:

[https://us02web.zoom.us/webinar/register/WN\\_xNLYNco0QW-UKaOywdMUkw](https://us02web.zoom.us/webinar/register/WN_xNLYNco0QW-UKaOywdMUkw)

The Executive Chair of Archer authorised this announcement to be given to ASX.

### Investor enquiries

Luke Maffei  
+61 403 193 579  
[luke.maffei@atomicgroup.com.au](mailto:luke.maffei@atomicgroup.com.au)

### Media enquiries

Dylan Mark  
+61 475 783 675  
[dylan.mark@atomicgroup.com.au](mailto:dylan.mark@atomicgroup.com.au)

### About Archer

Archer is a quantum technology company that operates within the semiconductor industry. The Company is developing advanced semiconductor devices, including chips relevant to quantum computing, sensing, and medical diagnostics. Archer utilises its global partnerships to develop these technologies for potential deployment and use across multiple industries.  
[www.archerx.com.au](http://www.archerx.com.au)



# 1H FY26 results

Dr Simon Ruffell, Chief Executive Officer

4 March 2026



# Archer at a Glance

Archer Materials (ASX: AXE) is the only ASX-listed quantum technology company. We are developing IP for use in quantum computing, sensing and medical diagnostics.



Technology roadmap of IP in medical, quantum sensing, and computing.



Development partnerships with world-class R&D institutions and industry leaders.



Headquarters in Australia.



Over 40 patents filed globally.

Quantum Computing

Biochip

Quantum Sensing

Quantum Machine Learning

# Quantum Machine Learning

- Archer has partnered with CSIRO to develop Quantum Machine Learning (QML) models for fraud detection
- Initial outputs: prototype QML fraud detection models and performance benchmarks on simulated financial datasets
- While fraud detection is the initial application, the underlying QML framework is broadly applicable.
- Creates optionality for Archer across multiple high-value sectors (e.g. healthcare, defence and aerospace, cybersecurity) while building defensible intellectual property.

**QML fraud detection project reinforces Archer's strategy to commercialise near-term quantum applications with global impact.**



# 1H FY26 Overview



# 1H FY26 Highlights

- **Overall**
  - **Advanced with technical derisking**
  - **Technology IP portfolio broadening**
- **<sup>12</sup>CQ carbon-based qubit material platform**
  - Achieved fundamental readout milestones for our carbon qubits
  - Entered collaboration agreement with Emergence Quantum
- **Quantum Sensing and TMR**
  - Demonstration of cryogenic TMR operation
  - Continuing to explore associated applications in advanced sensing, aerospace, and space exploration with potential customers/end-users
- **Quantum Machine Learning**
  - Entered collaboration agreement with CSIRO to develop QML models for financial fraud

**Towards qubit demo,  
sensing applications, and  
software**



# 1H FY26 Highlights

## Overall

- **Technical, supply-chain, manufacturability derisking.**
  - **Early system prototype - basis for partner meetings and pre-clinical testing.**
- 
- Improved route to commercialisation
    - Completed project with IMEC and demonstrated feasibility using silicon biochips.
- 
- Technical derisking
    - Completed Alpha prototype: early integration of test chip, cartridge, and readout electronics testing <10 µL of blood.
    - Allows for next step of beta prototype in 2026: pre-clinical studies and basis of negotiations with MedTech companies and engagement with medical device manufacturers.
- 
- Building the product platform
    - Collected early feasibility data for testing other ions in liquids e.g. lithium for mental health disorders.

**Moving toward biochip beta prototype demonstration in 2026**




Concept Image

# Outlook



# 2026 Key Milestones

Calendar years to 2027



- ▶ Lab demonstrator/alpha prototype of blood potassium delivered in early 2026.
- ▶ Blood potassium beta prototype sensor in 2026 for use in trials
- ▶ End of 2026 begin clinical trials for blood potassium sensor
- ▶ Targeting quantum sensing application and market validation early 2026 (TMR, carbon)
- ▶ Work to begin on development of next generation biosensor from R&D – early 2026
- ▶ Carbon-based quantum qubit demonstration (computing) & QML demonstration

# Disclaimer

The material contained in this document is a presentation of general information about the activities of Archer Materials Ltd and its related bodies corporate (together the “Archer Group”), current as at the date of this presentation. It is provided in summary and does not purport to be complete. You should not rely upon it as advice for investment purposes, as it does not take into account your investment objectives, financial position or needs. These factors should be considered, with or without professional advice, when deciding if an investment is appropriate.

To the extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining from acting as a result of this material is accepted by the Archer Group, including any of its related bodies corporate.

This document may contain forward-looking statements with respect to the financial condition, results of operations, and business strategy of the Archer Group. These forward-looking statements are based on estimates, projections and assumptions made by the Archer Group about circumstances and events that have not yet taken place. Although the Archer Group believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Archer Group’s control, and which may cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements (and from past results). The Archer Group makes no representation or warranty as to the accuracy of any forward-looking statements in this presentation and undue reliance should not be placed upon such statements. Forward-looking statements may be identified by words such as “aim”, “anticipate”, “assume”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “should”, “will”, or “would” or the negative of such terms or other similar expressions that are predictions of or otherwise indicate future events or trends. The forward-looking statements included in this presentation speak only as of the date of this presentation. The Archer Group does not intend to update the forward-looking statements in this presentation in the future.

This presentation contains information which was reported in ASX announcements lodged previously by the Company (together the “Announcements”). All material assumptions and technical parameters set out in the Announcements continue to apply and have not materially changed. The Announcements can be viewed online at [www.archerx.com.au](http://www.archerx.com.au).

Certain statistical and other information included in this presentation is sourced from publicly available third party sources and has not been independently verified.



# Thank you

ASX Code: AXE

**Sydney**

Level 2, 477 Pitt St  
Sydney NSW 2000

**Adelaide**

Lot Fourteen, Frome Rd  
Adelaide SA 5000

Subscribe to  
our newsletter

